Abstract
British Journal of DermatologyVolume 185, Issue 6 p. e202-e202 Plain Language Summary Mortality and associated diseases in patients with pyoderma gangrenosum: a Danish nationwide study First published: 17 December 2021 https://doi.org/10.1111/bjd.20789AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Linked Article: Ben Abdallah et al. Br J Dermatol 2021; 185:1169–1175. Pyoderma gangrenosum (PG) is a rare ulcerative skin disease associated with certain other diseases (comorbidities) such as inflammatory bowel and rheumatic diseases. There is little information available on this topic. Our study from Denmark aimed to find out whether patients with PG had comorbidities and a higher risk of death (mortality) than individuals without PG (controls). In Denmark, all visits to hospitals, including specialty clinics, are recorded in the Danish National Patient Registry. The Danish Civil Registration System contains basic personal information on all individuals living in Denmark. We used the information from these two registries to find 1604 patients with PG and 16,039 controls. We found that patients with PG had comorbidities that were previously known about, but we also found other comorbidities. Patients with PG were approximately three times more likely to die than individuals without PG. It is important to be aware of these associations because undiagnosed comorbidities may affect the health and quality of life of patients and ultimately lead to death. Volume185, Issue6December 2021Pages e202-e202 RelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
